SNDL
Sndl Inc
NASDAQ · Pharmaceuticals
$1.51
+0.06 (+4.14%)
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 897.13M | 64.47M | 59.12M | 71.20M |
| Net Income | -92,391,000 | 22.72M | 16.50M | 24.90M |
| EPS | — | — | — | — |
| Profit Margin | -10.3% | 35.2% | 27.9% | 35.0% |
| Rev Growth | +154.1% | +0.6% | +13.8% | -7.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 23.03M | 69.31M | 55.29M | 58.47M |
| Total Equity | 171.38M | 260.32M | 239.97M | 225.54M |
| D/E Ratio | 0.13 | 0.27 | 0.23 | 0.26 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 2.21M | 29.98M | 25.74M | 34.11M |
| Free Cash Flow | — | 15.79M | 14.78M | 25.53M |